Clinically, however, evidence remains limited, as studies in humans typically investigate other biomarkers instead of HIF-1α, with no clinical trials directly demonstrating reduced HIF-1α within breast cancer tumors. This evidence concerns the gene HIF1A and breast carcinoma.